

Mustafa Khasraw Mbchb,, Fracp, Frcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8736563/publications.pdf>

Version: 2024-02-01

195
papers

7,315
citations

101543

36
h-index

66911

78
g-index

211
all docs

211
docs citations

211
times ranked

10714
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
2	Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 259-266.	1.1	4
3	Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. <i>Clinical Cancer Research</i> , 2022, 28, 13-22.	7.0	4
4	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
5	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
6	New Approaches to Glioblastoma. <i>Annual Review of Medicine</i> , 2022, 73, 279-292.	12.2	14
7	Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer. <i>Qualitative Health Research</i> , 2022, 32, 426-439.	2.1	7
8	Low tumor mutational burden and immunotherapy in gliomas. <i>Trends in Cancer</i> , 2022, 8, 345-346.	7.4	5
9	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	3.7	18
10	Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	14
11	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 2180-2195.	7.0	12
12	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2078-TPS2078.	1.6	3
13	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG). <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
14	Characterization of industry relationships in oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 11025-11025.	1.6	0
15	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2076-TPS2076.	1.6	0
16	Management of glioblastoma: an Australian perspective. <i>Chinese Clinical Oncology</i> , 2021, 10, 42-42.	1.2	5
17	What is the burden of proof for tumor mutational burden in gliomas?. <i>Neuro-Oncology</i> , 2021, 23, 17-22.	1.2	15
18	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	7.0	222

#	ARTICLE	IF	CITATIONS
19	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
20	Salting the Soil: Targeting the Microenvironment of Brain Metastases. Molecular Cancer Therapeutics, 2021, 20, 455-466.	4.1	13
21	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF- β 2 and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab058.	0.7	13
22	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications, 2021, 12, 352.	12.8	77
23	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
24	The role of immunotherapy in fusion-driven lung cancer. Expert Review of Anticancer Therapy, 2021, 21, 461-464.	2.4	3
25	mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report. BMC Gastroenterology, 2021, 21, 194.	2.0	1
26	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 2021, 2021, CD011395.	2.8	19
27	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro-Oncology, 2021, 23, 1252-1260.	1.2	11
28	High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology, 2021, 32, 661-672.	1.2	586
29	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
30	A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.. Journal of Clinical Oncology, 2021, 39, 2585-2585.	1.6	3
31	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. Journal of Clinical Oncology, 2021, 39, 1091-1091.	1.6	5
32	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro-Oncology, 2021, 23, 1736-1749.	1.2	44
33	Targeting Immunometabolism in Glioblastoma. Frontiers in Oncology, 2021, 11, 696402.	2.8	19
34	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
35	Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells, 2021, 10, 2032.	4.1	12
36	A Modified Nucleoside 6-Thio-2-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10

#	ARTICLE	IF	CITATIONS
37	Reply to: "Real-world prevalence across 159,872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab."™ by D. Fabrizio et al.. Annals of Oncology, 2021, 32, 1194-1197.	1.2	2
38	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncology, The, 2021, 22, e456-e465.	10.7	53
39	A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuro-Oncology Advances, 2021, 3, vdaa146.	0.7	10
40	The microenvironment of brain metastases from solid tumors. Neuro-Oncology Advances, 2021, 3, v121-v132.	0.7	14
41	INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. Neuro-Oncology, 2021, 23, vi106-vi107.	1.2	0
42	EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. Neuro-Oncology, 2021, 23, vi3-vi3.	1.2	0
43	A sociology of precision "in" practice: The affective and temporal complexities of everyday clinical care. Sociology of Health and Illness, 2021, 43, 2178-2195.	2.1	14
44	INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE. Neuro-Oncology, 2021, 23, vi112-vi112.	1.2	0
45	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11
46	QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE. Neuro-Oncology, 2021, 23, vi189-vi189.	1.2	0
47	EXTH-82. T CELL HITCHHIKING AS A MECHANISM OF DRUG DELIVERY TO THE BRAIN. Neuro-Oncology, 2021, 23, vi182-vi182.	1.2	0
48	CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi51.	1.2	2
49	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies at relapse: Protocol for a pilot study. BMJ Open, 2021, 11, e054075.	1.9	2
50	Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlentherapie Und Onkologie, 2020, 196, 31-39.	2.0	6
51	Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. Neuro-Oncology Practice, 2020, 7, 31-37.	1.6	2
52	The epidemiology of emergency presentations for falls from height across Western Victoria, Australia. Australasian Emergency Care, 2020, 23, 119-125.	1.5	4
53	Molecular and clonal evolution in recurrent metastatic gliosarcoma. Journal of Physical Education and Sports Management, 2020, 6, a004671.	1.2	10
54	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. Clinical Cancer Research, 2020, 26, 5809-5813.	7.0	44

#	ARTICLE	IF	CITATIONS
55	Adapting to a Pandemic – Conducting Oncology Trials during the SARS-CoV-2 Pandemic. <i>Clinical Cancer Research</i> , 2020, 26, 3100-3103.	7.0	53
56	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2020, 2020, CD013238.	2.8	19
57	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	329.8	969
58	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020, 26, 5287-5296.	7.0	88
59	The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 33-39.	1.7	7
60	Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1416.	4.1	21
61	CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii37-ii37.	1.2	4
62	Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts. , 2020, , .		11
63	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2579-TPS2579.	1.6	5
64	RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii195-ii196.	1.2	0
65	COVID-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING. <i>Neuro-Oncology</i> , 2020, 22, ii26-ii26.	1.2	0
66	BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION. <i>Neuro-Oncology</i> , 2020, 22, ii5-ii5.	1.2	0
67	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2020, 22, ii38-ii38.	1.2	3
68	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	7.7	104
69	Traveling With Cancer: A Guide for Oncologists in the Modern World. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	3
70	Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma. <i>Cancer</i> , 2019, 125, 3457-3466.	4.1	3
71	Revision joint replacement surgeries of the hip and knee across geographic region and socioeconomic status in the western region of Victoria: a cross-sectional multilevel analysis of registry data. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 300.	1.9	3
72	Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. <i>Annals of Oncology</i> , 2019, 30, v498-v499.	1.2	4

#	ARTICLE	IF	CITATIONS
73	The epidemiology of emergency presentations for falls across Western Victoria, Australia. <i>Australasian Emergency Care</i> , 2019, 22, 206-215.	1.5	2
74	Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women. <i>BMC Cancer</i> , 2019, 19, 892.	2.6	9
75	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 272-280.	1.8	6
76	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. <i>Neuro-Oncology</i> , 2019, 21, 424-427.	1.2	27
77	Ibutilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). <i>Scientific Reports</i> , 2019, 9, 2905.	3.3	34
78	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. <i>Journal of Clinical Oncology</i> , 2019, 37, 1130-1135.	1.6	22
79	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trialâ€™Clinical outcomes and molecular determinants of response. <i>PLoS ONE</i> , 2019, 14, e0210891.	2.5	13
80	Association between area-level socioeconomic status, accessibility and diabetes-related hospitalisations: a cross-sectional analysis of data from Western Victoria, Australia. <i>BMJ Open</i> , 2019, 9, e026880.	1.9	5
81	ACTR-29. A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU. <i>Neuro-Oncology</i> , 2019, 21, vi19-vi19.	1.2	0
82	COMP-15. MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA. <i>Neuro-Oncology</i> , 2019, 21, vi64-vi64.	1.2	0
83	EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi79-vi79.	1.2	1
84	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2019, , .	2.8	4
85	ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITEÂ®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). <i>Neuro-Oncology</i> , 2019, 21, vi283-vi283.	1.2	14
86	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
87	The Epidemiology of Joint Replacements Across Western Victoria, Australia: a Cross-sectional Study. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 1038-1047.	0.6	0
88	ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi18-vi18.	1.2	1
89	A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2011-2011.	1.6	11
90	Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2042-2042.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. <i>JMIR Research Protocols</i> , 2019, 8, e14361.	1.0	3
92	Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. <i>Practical Radiation Oncology</i> , 2018, 8, 230-238.	2.1	22
93	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	1.2	119
94	Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. <i>Journal of Neuro-Oncology</i> , 2018, 137, 409-415.	2.9	53
95	Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the <sc>NEONAB</sc> trial. <i>Internal Medicine Journal</i> , 2018, 48, 699-705.	0.8	9
96	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	7.0	154
97	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 256-263.	1.1	8
98	The epidemiology of hip fractures across western Victoria, Australia. <i>Bone</i> , 2018, 108, 1-9.	2.9	14
99	ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2018, 20, vi4-vi4.	1.2	2
100	EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS. <i>Neuro-Oncology</i> , 2018, 20, vi82-vi83.	1.2	2
101	The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. <i>Oncotarget</i> , 2018, 9, 7844-7858.	1.8	29
102	RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS. <i>Neuro-Oncology</i> , 2018, 20, vi235-vi235.	1.2	1
103	P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress. <i>Neuro-Oncology</i> , 2018, 20, iii236-iii236.	1.2	0
104	Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre. <i>Brain Sciences</i> , 2018, 8, 186.	2.3	1
105	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. <i>Clinical Oncology</i> , 2018, 30, 556-562.	1.4	6
106	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	2.5	37
107	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, 313-319.	2.3	9
108	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	5.1	31

#	ARTICLE	IF	CITATIONS
109	Anti-angiogenic therapy for high-grade glioma. The Cochrane Library, 2018, 2018, CD008218.	2.8	81
110	A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU) Tj ETQq0 0 0.rgBT /Overlock 10 T	0.8	0
111	AGITG nabrec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.. Journal of Clinical Oncology, 2018, 36, TPS548-TPS548.	1.6	0
112	Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.. Journal of Clinical Oncology, 2018, 36, 1076-1076.	1.6	0
113	Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 802-810.	0.8	25
114	Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 2017, 19, 38.	4.0	18
115	Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. Journal of Translational Medicine, 2017, 15, 61.	4.4	34
116	Immune Checkpoint Inhibitors in Gliomas. Current Oncology Reports, 2017, 19, 23.	4.0	27
117	Reply to Dr Altundag from the authors of "Management of breast cancer brain metastases; a practical review"™. Breast, 2017, 34, 133.	2.2	0
118	Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry. Archives of Osteoporosis, 2017, 12, 97.	2.4	15
119	Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discovery, 2017, 3, 17033.	4.7	62
120	Management of breast cancer brain metastases: A practical review. Breast, 2017, 31, 90-98.	2.2	16
121	Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?. Clinical and Translational Oncology, 2017, 19, 273-278.	2.4	13
122	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017, 19, vi40-vi41.	1.2	0
123	P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide. Neuro-Oncology, 2017, 19, iii27-iii27.	1.2	0
124	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics, 2017, 7, 1149-1158.	10.0	201
125	Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.. Journal of Clinical Oncology, 2017, 35, 2062-2062.	1.6	14
126	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. Journal of Clinical Oncology, 2017, 35, 3572-3572.	1.6	1

#	ARTICLE	IF	CITATIONS
127	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2017, 35, 380-380.	1.6	6
128	Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia). Journal of Public Health Research, 2016, 5, jphr.2016.678.	1.2	11
129	SURG-06. OUTCOMES OF SECOND SURGERY FOR RECURRENT GLIOBLASTOMA MULTIFORME: A RETROSPECTIVE CASE CONTROL STUDY. Neuro-Oncology, 2016, 18, vi192-vi192.	1.2	1
130	Retrospective analysis of cancer survival across South-Western Victoria in Australia. Australian Journal of Rural Health, 2016, 24, 79-84.	1.5	3
131	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 2016, 18, 1357-1366.	1.2	116
132	A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 311-319.	4.9	17
133	Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of Neuro-Oncology, 2016, 128, 163-171.	2.9	38
134	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 2016, 34, 2258-2264.	1.6	52
135	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 2016, 102, 21-27.	2.0	11
136	A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)â€”CheckMate-548. Annals of Oncology, 2016, 27, vi113.	1.2	7
137	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	2.6	15
138	Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2016, 16, 391-401.	2.4	2
139	Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncolmmunology, 2016, 5, e1145332.	4.6	13
140	Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. Supportive Care in Cancer, 2016, 24, 3023-8.	2.2	2
141	Evolving management of low grade glioma: No consensus amongst treating clinicians. Journal of Clinical Neuroscience, 2016, 23, 81-87.	1.5	17
142	Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.. Journal of Clinical Oncology, 2016, 34, e12515-e12515.	1.6	0
143	CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs, 2015, 26, 797-806.	1.4	38
144	ATPS-54 GENOMICALLY UNSTABLE GLIOBLASTOMA (U-GBM) SHOW EXQUISITE SENSITIVITY TO PARP INHIBITION. Neuro-Oncology, 2015, 17, v30.2-v30.	1.2	0

#	ARTICLE	IF	CITATIONS
145	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. <i>Theranostics</i> , 2015, 5, 1456-1472.	10.0	84
146	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	27.0	1,239
147	Mutational analysis of matched initial and recurrent TP53 WT primary GBM.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2043-2043.	1.6	0
148	Identification of glioblastoma patients who stand to benefit from PARP inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2071-2071.	1.6	0
149	A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6527-6527.	1.6	0
150	Abstract A12: Genomically unstable glioblastoma are sensitive to Parp inhibition. , 2015, , .		1
151	Antiangiogenic therapy for high-grade glioma. <i>The Cochrane Library</i> , 2014, , CD008218.	2.8	84
152	Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 729-740.	3.1	41
153	Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. <i>BMJ Open</i> , 2014, 4, e004007.	1.9	80
154	Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 273-278.	1.1	21
155	Patterns of care in adult medulloblastoma: results of an international online survey. <i>Journal of Neuro-Oncology</i> , 2014, 120, 125-129.	2.9	17
156	Brain metastases in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 173-183.	2.4	8
157	Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2050-2050.	1.6	22
158	A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2047-2047.	1.6	0
159	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response) Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, e14536-e14536.	1.6	0
160	Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1135-TPS1135.	1.6	0
161	Abstract 3777: Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines. , 2014, , .		2
162	Use of targeted therapy in cancer patients in the end-of-life period.. <i>Journal of Clinical Oncology</i> , 2014, 32, 129-129.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Small bowel video capsule endoscopy: an overview. Expert Review of Gastroenterology and Hepatology, 2013, 7, 323-329.	3.0	37
164	Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurology, 2013, 13, 153.	1.8	25
165	Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2013, 13, 451-459.	2.4	4
166	Risk of metachronous breast cancer after <i>BRCA</i> mutationâ€™associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	4.1	58
167	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology, 2013, 15, 242-250.	1.2	83
168	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. Journal of Clinical Oncology, 2013, 31, TPS3649-TPS3649.	1.6	2
169	Intra-aortic metastases or intra-arterial thrombus?. International Journal of Case Reports and Images, 2013, 4, 368.	0.0	0
170	Alternative targeted therapy for early Her2 positive breast cancer. Gland Surgery, 2013, 2, 42-5.	1.1	2
171	Neurological Complications of Non-Hodgkin Lymphoma. , 2012, , 267-285.		1
172	Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology, 2012, 23, 458-463.	1.2	63
173	Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Review of Anticancer Therapy, 2012, 12, 1005-1013.	2.4	11
174	Bevacizumab for the treatment of high-grade glioma. Expert Opinion on Biological Therapy, 2012, 12, 1101-1111.	3.1	23
175	Using lithium as a neuroprotective agent in patients with cancer. BMC Medicine, 2012, 10, 131.	5.5	39
176	Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast, 2012, 21, 142-149.	2.2	151
177	Colorectal cancer: is the incidence rising in young Iraqi patients?. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 380-381.	1.1	4
178	Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. Current Breast Cancer Reports, 2012, 4, 66-74.	1.0	2
179	Paraneoplastic Syndromes Affecting the Nervous System. , 2012, , 1388-1394.		87
180	The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?. Current Oncology Reports, 2011, 13, 17-25.	4.0	32

#	ARTICLE	IF	CITATIONS
181	Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. <i>Clinical Investigation</i> , 2011, 1, 1545-1554.	0.0	4
182	16. Primary choriocarcinoma of the colon – a case report. <i>Pathology</i> , 2010, 42, S85-S86.	0.6	1
183	Advances in the Treatment of Malignant Gliomas. <i>Current Oncology Reports</i> , 2010, 12, 26-33.	4.0	107
184	Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 177-179.	2.5	6
185	Neurological complications of systemic cancer. <i>Lancet Neurology</i> , The, 2010, 9, 1214-1227.	10.2	64
186	Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. <i>Internal Medicine Journal</i> , 2010, 40, 453-458.	0.8	5
187	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2010, 21, 1302-1307.	1.2	52
188	Late neurocognitive decline after radiotherapy for low-grade glioma. <i>Nature Reviews Neurology</i> , 2009, 5, 646-647.	10.1	27
189	Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?. <i>Annals of Oncology</i> , 2009, 20, 1282-1283.	1.2	8
190	Cardiac toxicity from sunitinib: Do we need to be more vigilant?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 217-218.	1.1	1
191	Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 854-855.	1.5	37
192	Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 838-847.	2.2	22
193	Anti-angiogenic therapy for lung cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0
194	Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0
195	Patterns of care in adult histone mutant gliomas: results of an international survey. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	0